EA200900613A1 - Спирокетоновые ингибиторы ацетил-коа-карбоксилаз - Google Patents

Спирокетоновые ингибиторы ацетил-коа-карбоксилаз

Info

Publication number
EA200900613A1
EA200900613A1 EA200900613A EA200900613A EA200900613A1 EA 200900613 A1 EA200900613 A1 EA 200900613A1 EA 200900613 A EA200900613 A EA 200900613A EA 200900613 A EA200900613 A EA 200900613A EA 200900613 A1 EA200900613 A1 EA 200900613A1
Authority
EA
Eurasian Patent Office
Prior art keywords
carboxylas
spiroketone
coa
acetyl
inhibitors
Prior art date
Application number
EA200900613A
Other languages
English (en)
Inventor
Джеффри Уэйн Корбетт
Ричард Луис Эллиотт
Эндрю Саймон Белл
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200900613A1 publication Critical patent/EA200900613A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В изобретении предложены соединения формулы (1)или фармацевтически приемлемые соли указанных соединений, где R, R, R, R, R, R, R, Rи Rявляются такими, как описано в данном изобретении; их фармацевтические композиции; и их применение в лечении млекопитающих, страдающих от состояния избыточной массы тела.
EA200900613A 2006-11-29 2007-11-16 Спирокетоновые ингибиторы ацетил-коа-карбоксилаз EA200900613A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86177906P 2006-11-29 2006-11-29
PCT/IB2007/003639 WO2008065508A1 (en) 2006-11-29 2007-11-16 Spiroketone acetyl-coa carboxylase inhibitors

Publications (1)

Publication Number Publication Date
EA200900613A1 true EA200900613A1 (ru) 2009-10-30

Family

ID=39126209

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900613A EA200900613A1 (ru) 2006-11-29 2007-11-16 Спирокетоновые ингибиторы ацетил-коа-карбоксилаз

Country Status (23)

Country Link
US (1) US20090270435A1 (ru)
EP (1) EP2097420B1 (ru)
JP (1) JP2010511035A (ru)
KR (1) KR20090083956A (ru)
CN (1) CN101541809A (ru)
AP (1) AP2009004880A0 (ru)
AT (1) ATE552262T1 (ru)
AU (1) AU2007326950B2 (ru)
BR (1) BRPI0721053A2 (ru)
CA (1) CA2670422C (ru)
CO (1) CO6180424A2 (ru)
CR (1) CR10831A (ru)
EA (1) EA200900613A1 (ru)
EC (1) ECSP099371A (ru)
IL (1) IL198779A0 (ru)
MA (1) MA30932B1 (ru)
MX (1) MX2009005604A (ru)
NO (1) NO20091889L (ru)
RS (1) RS20090249A (ru)
SV (1) SV2009003281A (ru)
TN (1) TN2009000204A1 (ru)
WO (1) WO2008065508A1 (ru)
ZA (1) ZA200903268B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540337C2 (ru) * 2010-10-29 2015-02-10 Пфайзер Инк. N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2120569B1 (en) * 2007-01-12 2013-08-14 Merck Sharp & Dohme Corp. Spirochromanon derivatives
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
CN100550853C (zh) * 2007-01-25 2009-10-14 华为技术有限公司 一种基于输出队列的流控实现方法及装置
DE102007028521A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
US20110009443A1 (en) * 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
EP2297163B1 (en) 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
WO2010002010A1 (en) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
JP2011528034A (ja) 2008-07-14 2011-11-10 クロップソリューション，インコーポレイテッド アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
EP2184276A1 (en) 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
PE20121469A1 (es) * 2009-11-10 2012-11-01 Pfizer Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa
CA2778316A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
HUE025774T2 (en) 2010-03-19 2016-05-30 Pfizer 2,3-Dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
CA2812526A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
PT2621493T (pt) 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
AU2012212196B2 (en) 2011-02-02 2016-10-13 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
CA2827311A1 (en) * 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
CA2829803A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
PL2699576T3 (pl) 2011-04-22 2016-05-31 Pfizer Pochodne pirazolospiroketonu do zastosowania jako inhibitory karboksylazy acetylo-COA
KR101953407B1 (ko) 2011-07-08 2019-02-28 바이엘 인텔렉쳐 프로퍼티 게엠베하 2-아미노-5-시아노-n,3-디메틸벤즈아미드의 제조 방법
JP2014520879A (ja) 2011-07-15 2014-08-25 ファイザー・インク Ｇｐｒ１１９調節因子
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
JP5601422B2 (ja) 2011-08-18 2014-10-08 日本新薬株式会社 ヘテロ環誘導体及び医薬
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
UA108713C2 (xx) 2011-11-11 2015-05-25 2-тіопіримідинони
MA37385B1 (fr) 2012-04-06 2019-09-30 Pfizer Inc Etat De Delaware Inhibiteurs de diacylglycérol-acyltransférase 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
EP2897964A1 (en) 2012-09-20 2015-07-29 Pfizer Inc. Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
CA2893256A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2015052610A1 (en) 2013-10-09 2015-04-16 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
AP2016009407A0 (en) 2014-03-17 2016-08-31 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
SG11201608110WA (en) 2014-04-04 2016-10-28 Pfizer Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA030085B1 (ru) 2014-04-10 2018-06-29 Пфайзер Инк. 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
WO2016103097A1 (en) 2014-12-22 2016-06-30 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
MX2017014128A (es) 2015-05-05 2018-03-15 Pfizer 2-tiopirimidinonas.
JP2018516254A (ja) 2015-05-29 2018-06-21 ファイザー・インク バニン１酵素の阻害薬としての新規なヘテロ環化合物
EP3310784B1 (en) 2015-06-17 2020-10-07 Pfizer Inc Tricyclic compounds and their use as phosphodiesterase inhibitors.
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
BR112018002071A2 (pt) 2015-08-13 2018-09-18 Pfizer compostos heteroarílicos ou arílicos fundidos bicíclicos
KR102029124B1 (ko) 2015-08-27 2019-10-07 화이자 인코포레이티드 Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
TN2018000198A1 (en) 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
JP2019524716A (ja) 2016-07-14 2019-09-05 ファイザー・インク バニン１酵素の阻害薬としての新規のピリミジンカルボキサミド
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
CN108658938B (zh) * 2018-06-15 2021-03-23 上海现代制药股份有限公司 一种甲磺酸达比加群酯工艺杂质的合成方法
CN108774242B (zh) * 2018-08-22 2020-10-27 牡丹江医学院 一种防治冠心病的药物及其制备方法
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
CN109400618B (zh) * 2018-11-09 2021-08-10 中国药科大学 一种色满衍生物及其制备方法和应用
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
CN109809992A (zh) * 2019-02-16 2019-05-28 安徽华胜医药科技有限公司 一种2-（2-氟-3-甲氧基苯基）-2-羟基乙酸乙酯的合成方法
CA3140972A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN110128347A (zh) * 2019-06-17 2019-08-16 韶远科技（上海)有限公司 一种1-甲基-1h-吲唑-6-甲酸的合成方法
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2022095971A1 (zh) * 2020-11-06 2022-05-12 上海医药集团股份有限公司 一种螺杂环类化合物、其制备方法及应用
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
CA2221842A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
WO2002020509A2 (de) * 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Arzneimittel gegen virale erkrankungen
JPWO2004092179A1 (ja) * 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) * 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
US8138342B2 (en) * 2004-10-12 2012-03-20 High Point Pharmacueticals, LLC 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
JP2008540395A (ja) * 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
WO2007011811A1 (en) * 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540337C2 (ru) * 2010-10-29 2015-02-10 Пфайзер Инк. N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ

Also Published As

Publication number Publication date
EP2097420A1 (en) 2009-09-09
CA2670422C (en) 2011-09-06
AP2009004880A0 (en) 2009-06-30
CO6180424A2 (es) 2010-07-19
SV2009003281A (es) 2010-08-17
CA2670422A1 (en) 2008-06-05
ATE552262T1 (de) 2012-04-15
AU2007326950B2 (en) 2010-10-14
WO2008065508A1 (en) 2008-06-05
JP2010511035A (ja) 2010-04-08
IL198779A0 (en) 2010-02-17
TN2009000204A1 (fr) 2010-10-18
MA30932B1 (fr) 2009-11-02
ZA200903268B (en) 2010-07-28
NO20091889L (no) 2009-06-17
CR10831A (es) 2009-06-18
RS20090249A (en) 2010-06-30
BRPI0721053A2 (pt) 2014-07-29
CN101541809A (zh) 2009-09-23
MX2009005604A (es) 2009-06-08
KR20090083956A (ko) 2009-08-04
ECSP099371A (es) 2009-06-30
US20090270435A1 (en) 2009-10-29
AU2007326950A1 (en) 2008-06-05
EP2097420B1 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
WO2009144555A8 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
EA200970156A1 (ru) Пиридизиноновые производные
EA200801997A1 (ru) Новые соединения
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA201070786A1 (ru) Бензофуропиримидиноны
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA200700902A1 (ru) 3-ариламинопиридиновые производные
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EA201000050A1 (ru) Замещенные бициклолактамные соединения
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
RS50720B (sr) 3,11 b-cis-dihidrotetrabenazin za lečenje proliferativne bolesti ili inflamacije